Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases.
Stock is 

Investor Overview

Analyst Coverage

Firm Analyst
Peter Lawson
Canaccord Genuity
John Newman Ph.D.
Cantor Fitzgerald
Alethia Young
Mohit Bansal
Marc Frahm
Goldman Sachs
Salveen Richter
Guggenheim Partners
Michael Schmidt Ph.D.
H.C. Wainright
Mike King
JP Morgan
Anupam Rama
Leerink Partners
Andrew Berens M.D.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.